Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers.

López-Ruiz A, del Peso-Gilsanz C, Meoro-Avilés A, Soriano-Palao J, Andreu A, Cabezuelo J, Arias JL

Pharmacy world & science : PWS5 Aug 2010Cited by 28 (Europe PMC)

PMID20686848DOI10.1007/s11096-010-9423-8PepBankPUB-20686848

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesSafety outcome
A man receiving exenatide with a diuretic and an angiotensin II receptor antagonist developed continuous nausea.
In plain wordsA man developed continuous nausea during treatment with exenatide, a diuretic, and an angiotensin II receptor antagonist.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableContinuous nausea
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Two months later, the patient exhibited a very important intolerance to exenatide (continuous nausea, vomiting, and dehydration), finally leading to ischemic acute renal failure.
2 context sentences(design, population, supporting numbers)
Summary · context
Case (description) the patient is a 20 years old male smoker, who was diagnosed with type 2 diabetes mellitus in 2006.
Summary · context
Due to the inadequate response to the previously established treatment, the pharmacotherapy was modified by introducing exenatide (up to 10 μg, twice daily) instead of insulin glargine, but maintaining the treatment with the diuretic and angiotensin II receptor antagonist drugs.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068684801
02HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesSafety outcome
A man receiving the exenatide-containing regimen developed vomiting.
In plain wordsA man developed vomiting during the exenatide-containing regimen.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableVomiting
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Two months later, the patient exhibited a very important intolerance to exenatide (continuous nausea, vomiting, and dehydration), finally leading to ischemic acute renal failure.
2 context sentences(design, population, supporting numbers)
Summary · context
Case (description) the patient is a 20 years old male smoker, who was diagnosed with type 2 diabetes mellitus in 2006.
Summary · context
Due to the inadequate response to the previously established treatment, the pharmacotherapy was modified by introducing exenatide (up to 10 μg, twice daily) instead of insulin glargine, but maintaining the treatment with the diuretic and angiotensin II receptor antagonist drugs.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068684802
03HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesSafety outcome
A man receiving the exenatide-containing regimen developed dehydration.
In plain wordsA man developed dehydration during the exenatide-containing regimen.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableDehydration
Study
n = 1
Outcome group
Adverse events · Whole body
Source sentences
Summary
Two months later, the patient exhibited a very important intolerance to exenatide (continuous nausea, vomiting, and dehydration), finally leading to ischemic acute renal failure.
2 context sentences(design, population, supporting numbers)
Summary · context
Case (description) the patient is a 20 years old male smoker, who was diagnosed with type 2 diabetes mellitus in 2006.
Summary · context
Due to the inadequate response to the previously established treatment, the pharmacotherapy was modified by introducing exenatide (up to 10 μg, twice daily) instead of insulin glargine, but maintaining the treatment with the diuretic and angiotensin II receptor antagonist drugs.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068684803
04HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesSafety outcome
A man receiving the exenatide-containing regimen developed ischemic acute renal failure after gastrointestinal intolerance and dehydration.
In plain wordsA man developed acute kidney failure after nausea, vomiting, and dehydration during the exenatide-containing regimen.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableIschemic acute renal failure
Study
n = 1
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Two months later, the patient exhibited a very important intolerance to exenatide (continuous nausea, vomiting, and dehydration), finally leading to ischemic acute renal failure.
2 context sentences(design, population, supporting numbers)
Summary · context
Case (description) the patient is a 20 years old male smoker, who was diagnosed with type 2 diabetes mellitus in 2006.
Summary · context
Due to the inadequate response to the previously established treatment, the pharmacotherapy was modified by introducing exenatide (up to 10 μg, twice daily) instead of insulin glargine, but maintaining the treatment with the diuretic and angiotensin II receptor antagonist drugs.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068684804
05HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesOther
The patient's renal function recovered rapidly after withdrawal of exenatide and the angiotensin II receptor antagonist.
In plain wordsThe man's kidney function recovered rapidly after doctors stopped exenatide and the angiotensin II receptor antagonist.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseRenal function after withdrawal
Study
n = 1
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
When the angiotensin II receptor antagonist and exenatide were suspended, a very rapid recovery of renal function was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Case (description) the patient is a 20 years old male smoker, who was diagnosed with type 2 diabetes mellitus in 2006.
Summary · context
Due to the inadequate response to the previously established treatment, the pharmacotherapy was modified by introducing exenatide (up to 10 μg, twice daily) instead of insulin glargine, but maintaining the treatment with the diuretic and angiotensin II receptor antagonist drugs.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2068684805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.